JP6863893B2 - 抗突然変異ｋｒａｓ ｔ細胞受容体 - Google Patents

抗突然変異ｋｒａｓ ｔ細胞受容体 Download PDF

Info

Publication number
JP6863893B2
JP6863893B2 JP2017527874A JP2017527874A JP6863893B2 JP 6863893 B2 JP6863893 B2 JP 6863893B2 JP 2017527874 A JP2017527874 A JP 2017527874A JP 2017527874 A JP2017527874 A JP 2017527874A JP 6863893 B2 JP6863893 B2 JP 6863893B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chain
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017527874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536825A (ja
JP2017536825A5 (cg-RX-API-DMAC7.html
Inventor
ジェイ． ワン、チョン
ジェイ． ワン、チョン
ユ、ジヤ
シー． ヤン、ジェームズ
シー． ヤン、ジェームズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2017536825A publication Critical patent/JP2017536825A/ja
Publication of JP2017536825A5 publication Critical patent/JP2017536825A5/ja
Priority to JP2021063092A priority Critical patent/JP7297807B2/ja
Application granted granted Critical
Publication of JP6863893B2 publication Critical patent/JP6863893B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
JP2017527874A 2014-11-26 2015-11-24 抗突然変異ｋｒａｓ ｔ細胞受容体 Active JP6863893B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021063092A JP7297807B2 (ja) 2014-11-26 2021-04-01 抗突然変異ｋｒａｓ ｔ細胞受容体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462084654P 2014-11-26 2014-11-26
US62/084,654 2014-11-26
US201562171321P 2015-06-05 2015-06-05
US62/171,321 2015-06-05
PCT/US2015/062269 WO2016085904A1 (en) 2014-11-26 2015-11-24 Anti-mutated kras t cell receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021063092A Division JP7297807B2 (ja) 2014-11-26 2021-04-01 抗突然変異ｋｒａｓ ｔ細胞受容体

Publications (3)

Publication Number Publication Date
JP2017536825A JP2017536825A (ja) 2017-12-14
JP2017536825A5 JP2017536825A5 (cg-RX-API-DMAC7.html) 2019-01-10
JP6863893B2 true JP6863893B2 (ja) 2021-04-21

Family

ID=54838442

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017527874A Active JP6863893B2 (ja) 2014-11-26 2015-11-24 抗突然変異ｋｒａｓ ｔ細胞受容体
JP2021063092A Active JP7297807B2 (ja) 2014-11-26 2021-04-01 抗突然変異ｋｒａｓ ｔ細胞受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021063092A Active JP7297807B2 (ja) 2014-11-26 2021-04-01 抗突然変異ｋｒａｓ ｔ細胞受容体

Country Status (17)

Country Link
US (3) US11207394B2 (cg-RX-API-DMAC7.html)
EP (3) EP3666288B1 (cg-RX-API-DMAC7.html)
JP (2) JP6863893B2 (cg-RX-API-DMAC7.html)
KR (1) KR102622784B1 (cg-RX-API-DMAC7.html)
CN (3) CN113956349B (cg-RX-API-DMAC7.html)
AU (3) AU2015353720B2 (cg-RX-API-DMAC7.html)
CA (1) CA2968399A1 (cg-RX-API-DMAC7.html)
ES (2) ES2784261T3 (cg-RX-API-DMAC7.html)
HU (1) HUE065689T2 (cg-RX-API-DMAC7.html)
IL (1) IL252258B (cg-RX-API-DMAC7.html)
MX (1) MX384919B (cg-RX-API-DMAC7.html)
PL (1) PL3223850T3 (cg-RX-API-DMAC7.html)
PT (1) PT3223850T (cg-RX-API-DMAC7.html)
SA (1) SA517381608B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201913978RA (cg-RX-API-DMAC7.html)
SI (1) SI3223850T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016085904A1 (cg-RX-API-DMAC7.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11207394B2 (en) * 2014-11-26 2021-12-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated KRAS T cell receptors
EP3350213B1 (en) * 2015-09-15 2021-03-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-cw8 restricted mutated kras
HUE060121T2 (hu) 2016-08-02 2023-01-28 The U S A As Represented By The Secretary Anti-KRAS-G12D T-sejt receptorok
WO2018069871A2 (en) 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Anti-kras binding proteins
DK3558339T5 (da) 2016-12-22 2024-09-02 Cue Biopharma Inc T-celle-modulerende multimere polypeptider og fremgangsmåder til anvendelse deraf
CN108395479B (zh) * 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
CN110612116A (zh) 2017-05-08 2019-12-24 磨石肿瘤生物技术公司 甲病毒新抗原载体
CN110662760A (zh) 2017-05-12 2020-01-07 奥古斯塔大学研究所公司 人甲胎蛋白特异性t细胞受体及其用途
US11807662B2 (en) 2017-05-16 2023-11-07 The Johns Hopkins University MANAbodies and methods of using
CN111201237B (zh) * 2017-09-20 2025-03-25 美国卫生和人力服务部 针对突变的ras的hlaii类限制性t细胞受体
SG11202002635RA (en) * 2017-09-29 2020-04-29 The United States Of America As Represented By The Secretary Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
CA3077595A1 (en) 2017-10-05 2019-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for diagnosing, monitoring and treating neurological diseases and disorders
EP3720478A1 (en) * 2017-12-04 2020-10-14 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class i-restricted t cell receptors against mutated ras
CN110016074B (zh) * 2018-01-08 2021-03-30 中国科学院广州生物医药与健康研究院 Mage-a3人源化t细胞受体
WO2019246286A1 (en) * 2018-06-19 2019-12-26 Neon Therapeutics, Inc. Neoantigens and uses thereof
CN112888707B (zh) * 2018-08-16 2025-04-25 百欧恩泰美国公司 T细胞受体构建体及其用途
CN120607607A (zh) * 2019-01-22 2025-09-09 美国卫生和人力服务部 针对含有g12r突变的ras的hla第ii类限制性t细胞受体
SG11202108039QA (en) * 2019-01-25 2021-08-30 Univ Pennsylvania Compositions and methods for targeting mutant ras
JP2022521513A (ja) * 2019-02-20 2022-04-08 フレッド ハッチンソン キャンサー リサーチ センター Ｒａｓネオ抗原に特異的な結合タンパク質およびその使用
WO2020210202A1 (en) * 2019-04-11 2020-10-15 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
KR20220013569A (ko) * 2019-05-27 2022-02-04 프로빈셜 헬스 서비시즈 오쏘리티 Kras 항원을 표적화하는 면역요법용 구조체
TW202523847A (zh) 2019-05-30 2025-06-16 美商磨石生物公司 經修飾之腺病毒
CA3142404A1 (en) * 2019-06-07 2020-12-10 Emory University Kras g12v mutant binds to jak1, inhibitors, pharmaceutical compositions, and methods related thereto
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
EP3997131A4 (en) 2019-07-12 2023-08-02 The Regents of the University of California Chemically controlled monoclonal antibody target engagement
CN112646024B (zh) * 2019-10-10 2023-03-24 香雪生命科学技术（广东）有限公司 一种识别kras突变的t细胞受体及其编码序列
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
WO2021087840A1 (zh) * 2019-11-07 2021-05-14 武汉华大吉诺因生物科技有限公司 肿瘤免疫治疗多肽及其应用
IL292535A (en) * 2019-11-15 2022-06-01 Gritstone Bio Inc Antigen-binding proteins that target shared neoantigens
KR20220143867A (ko) * 2020-02-12 2022-10-25 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 G12d 돌연변이를 갖는 ras에 대한 hla 클래스 i-제한된 t 세포 수용체
US20230082787A1 (en) * 2020-02-14 2023-03-16 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla class i-restricted t cell receptors against ras with g12v mutation
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
CN113684258B (zh) * 2020-05-18 2024-08-20 上海赛比曼生物科技有限公司 用于检测鼠源tcr转基因拷贝数的试剂盒及方法
US20230181714A1 (en) * 2020-05-27 2023-06-15 Vanderbilt University Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor
WO2022015922A1 (en) * 2020-07-16 2022-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted drb t cell receptors against ras with g12v mutation
EP4192496A4 (en) 2020-08-06 2025-01-01 Gritstone bio, Inc. MULTIEPITOP VACCINE CASSETTES
CN112300269B (zh) * 2020-09-29 2022-12-09 中国科学院微生物研究所 Kras突变特异性t细胞受体筛选及抗肿瘤用途
TW202229327A (zh) * 2020-10-02 2022-08-01 美國衛生與公眾服務部 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體
CA3202725A1 (en) * 2020-11-24 2022-06-02 Shanghai GenBase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
WO2022197971A1 (en) * 2021-03-19 2022-09-22 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
CN116063511B (zh) * 2021-09-30 2023-10-03 北京可瑞生物科技有限公司 抗原结合蛋白及其应用
KR102818249B1 (ko) * 2021-11-11 2025-06-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법
KR102753583B1 (ko) * 2021-11-11 2025-01-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
CN118574843A (zh) 2022-01-21 2024-08-30 T-Knife 股份有限公司 以可检测的亲和力结合特异性肽的抗原识别构建体和对kras具有抗原特异性的t细胞受体以及相应的核酸序列、载体、宿主细胞、药物组合物和试剂盒
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
CN114591443A (zh) * 2022-03-07 2022-06-07 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种基于scTv的嵌合受体CSR及其应用
CN114835800B (zh) * 2022-05-27 2023-10-13 重庆医科大学 Tcr或其抗原结合片段及其应用
CN114920824B (zh) * 2022-05-27 2023-12-05 重庆医科大学 Tcr或其抗原结合片段及其应用
WO2024055003A1 (en) * 2022-09-08 2024-03-14 The Regents Of The University Of California Binding agent recognition of drug-peptide conjugates
WO2024147556A1 (ko) * 2023-01-05 2024-07-11 의료법인 명지의료재단 K-ras 돌연변이 다중 항원결정기 폴리펩타이드를 유효성분으로 포함하는 항암 백신용 조성물
IL322077A (en) * 2023-01-13 2025-09-01 Corregene Biotechnology Co Ltd Antigen-binding protein and its use
CN118812698A (zh) * 2023-04-19 2024-10-22 香雪生命科学技术（广东）有限公司 一种识别kras突变的高亲和力t细胞受体及其应用
CN118909132A (zh) * 2023-05-06 2024-11-08 北京鼎成肽源生物技术有限公司 靶向kras g12v突变的tcr分子和细胞及其应用
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
CN116574748B (zh) * 2023-07-10 2023-09-12 昆明医科大学 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法
CN117143823B (zh) * 2023-09-11 2024-07-16 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种基于tcr单链可变区的靶向ras(g12v)的嵌合抗原受体记忆nk细胞的研制及其应用
WO2025056656A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR VARIANT AGAINST mKRAS7-16 G12V
WO2025056681A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR AGAINST mKRAS7-16 G12V AND G12C

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709002B1 (en) * 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
US8486694B2 (en) * 2005-08-05 2013-07-16 Helmholtz Zentrum Muenchen Deutsches Forschungzentrum fuer Gesundheit und Umwelt GmbH Generation of antigen specific T cells
AU2007248019B2 (en) * 2006-05-03 2012-10-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric T cell receptors and related materials and methods of use
US8216565B2 (en) * 2007-01-12 2012-07-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services GP100-specific T cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2011034906A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
CN104131034B (zh) * 2014-06-19 2017-04-05 中山大学 一种嵌合载体及其制备方法和应用
US11207394B2 (en) * 2014-11-26 2021-12-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated KRAS T cell receptors
CN105802909B (zh) * 2014-12-31 2021-01-01 中国医学科学院基础医学研究所 具有her2特异性tcr的t细胞制备物及其用途
CN108395479B (zh) * 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
CN113621070A (zh) * 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用

Also Published As

Publication number Publication date
EP3223850A1 (en) 2017-10-04
CA2968399A1 (en) 2016-06-02
JP2017536825A (ja) 2017-12-14
JP2021104044A (ja) 2021-07-26
ES2965689T3 (es) 2024-04-16
AU2020203465A1 (en) 2020-06-18
EP4286407A2 (en) 2023-12-06
EP4286407A3 (en) 2024-03-06
AU2015353720B2 (en) 2020-02-27
CN118994363A (zh) 2024-11-22
EP3666288A1 (en) 2020-06-17
CN113956349A (zh) 2022-01-21
AU2020203465B2 (en) 2022-11-17
SI3223850T1 (sl) 2020-09-30
HUE065689T2 (hu) 2024-06-28
MX384919B (es) 2025-03-14
SG10201913978RA (en) 2020-03-30
US12312391B2 (en) 2025-05-27
NZ732045A (en) 2024-04-26
AU2015353720A1 (en) 2017-06-08
KR20170099905A (ko) 2017-09-01
US20250263462A1 (en) 2025-08-21
EP3666288B1 (en) 2023-09-27
IL252258A0 (en) 2017-07-31
CN107223134B (zh) 2021-11-16
AU2023200614A1 (en) 2023-03-09
US20170304421A1 (en) 2017-10-26
US20220088164A1 (en) 2022-03-24
ES2784261T3 (es) 2020-09-23
JP7297807B2 (ja) 2023-06-26
KR102622784B1 (ko) 2024-01-09
PL3223850T3 (pl) 2020-08-24
WO2016085904A1 (en) 2016-06-02
IL252258B (en) 2021-12-01
PT3223850T (pt) 2020-04-13
SA517381608B1 (ar) 2021-03-11
HK1243642A1 (en) 2018-07-20
US11207394B2 (en) 2021-12-28
SG11201704155UA (en) 2017-06-29
EP3223850B1 (en) 2020-01-08
CN113956349B (zh) 2024-09-06
CN107223134A (zh) 2017-09-29
MX2017006865A (es) 2018-01-11

Similar Documents

Publication Publication Date Title
US12312391B2 (en) Anti-mutated KRAS T cell receptors
US12187779B2 (en) Anti-human papillomavirus 16 E6 T cell receptors
JP6997267B2 (ja) 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体
JP2023175703A (ja) 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
HK40031837A (en) Anti-mutated kras t cell receptors
HK40031837B (en) Anti-mutated kras t cell receptors
HK40065450B (zh) 抗突变的kras的t细胞受体
HK40018191A (en) Anti-human papillomavirus 16 e6 t cell receptors
HK1243642B (en) Anti-mutated kras t cell receptors

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210302

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210401

R150 Certificate of patent or registration of utility model

Ref document number: 6863893

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250